Effects of the Lipid Profile, Type 2 Diabetes and Medication on the Metabolic Syndrome—Associated Gut Microbiome

dc.contributor.authorGradisteanu Pircalabioru, Gratiela
dc.contributor.authorLiaw, Janie
dc.contributor.authorGundogdu, Ozan
dc.contributor.authorCorcionivoschi, Nicolae
dc.contributor.authorIlie, Iuliana
dc.contributor.authorOprea, Luciana
dc.contributor.authorMusat, Madalina
dc.contributor.authorChifiriuc, Mariana-Carmen
dc.date.accessioned2022-07-11T14:34:01Z
dc.date.available2022-07-11T14:34:01Z
dc.date.issued2022-07-06
dc.descriptionPublication history: Accepted - 4 July 2022; Published online - 6 July 2022en_US
dc.description.abstractMetabolic syndrome (MetSyn) is a major health problem affecting approximately 25% of the worldwide population. Since the gut microbiota is highly connected to the host metabolism, several recent studies have emerged to characterize the role of the microbiome in MetSyn development and progression. To this end, our study aimed to identify the microbiome patterns which distinguish MetSyn from type 2 diabetes mellitus (T2DM). We performed 16S rRNA amplicon sequencing on a cohort of 70 individuals among which 40 were MetSyn patients. The microbiome of MetSyn patients was characterised by reduced diversity, loss of butyrate producers (Subdoligranulum, Butyricicoccus, Faecalibacterium prausnitzii) and enrichment in the relative abundance of fungal populations. We also show a link between the gut microbiome and lipid metabolism in MetSyn. Specifically, low-density lipoproteins (LDL) and high-density lipoproteins (HDL) display a positive effect on gut microbial diversity. When interrogating the signature of gut microbiota in a subgroup of patients harbouring both MetSyn and T2DM conditions, we observed a significant increase in taxa such as Bacteroides, Clostridiales, and Erysipelotrichaceae. This preliminary study shows for the first time that T2DM brings unique signatures of gut microbiota in MetSyn patients. We also highlight the impact of metformin treatment on the gut microbiota. Metformin administration was linked to changes in Prevotellaceae, Rickenellaceae, and Clostridiales. Further research focusing on the microbiome-metabolome patterns is needed to clarify the exact association of various gut microbial communities with the progression of T2DM and the occurrence of various complications in MetSyn patientsen_US
dc.description.sponsorshipThis research was funded by UEFISCDI, project ID PN-III-P1-1.1-36PD-2019-0499, Grant number 224/2021 and C1.2.PFE-CDI.2021-587.en_US
dc.identifierhttp://hdl.handle.net/20.500.12518/469
dc.identifier.citationGradisteanu Pircalabioru, G., Liaw, J., Gundogdu, O., Corcionivoschi, N., Ilie, I., Oprea, L., Musat, M. and Chifiriuc, M.-C. (2022) ‘Effects of the Lipid Profile, Type 2 Diabetes and Medication on the Metabolic Syndrome—Associated Gut Microbiome’, International Journal of Molecular Sciences. MDPI AG. doi:10.3390/ijms23147509.en_US
dc.identifier.issn1661-6596
dc.identifier.issn1422-0067
dc.identifier.urihttps://doi.org/10.3390/ijms23147509
dc.language.isoenen_US
dc.publisherMDPIen_US
dc.rights© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).en_US
dc.subjectmetabolic syndromeen_US
dc.subjectdiabetesen_US
dc.subjectmicrobiomeen_US
dc.subjectdysbiosisen_US
dc.subjectMetforminen_US
dc.titleEffects of the Lipid Profile, Type 2 Diabetes and Medication on the Metabolic Syndrome—Associated Gut Microbiomeen_US
dc.typeArticleen_US
dcterms.dateAccepted2022-07-04
dcterms.dateSubmitted2022-04-22

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Effects of the Lipid Profile, Type 2 Diabetes and Medication on the Metabolic Syndrome—Associated Gut Microbiome.pdf
Size:
2.26 MB
Format:
Adobe Portable Document Format
Description:
Final published version

Collections